The FDA issued a warning concerning rare instances of serious liver injury or failure from direct-acting antivirals (DAAs) used to treat hepatitis C virus (HCV) infection.
The agency identified 63 cases of liver decompensation, some leading to liver failure or death, in patients using glecaprevir/pibrentasvir (Mavyret, AbbVie), elbasvir/grazoprevir (Zepatier, Merck), and sofosbuvir/velpatasvir (Vosevi, Gilead).